Alnylam Pharmaceuticals (NASDAQ:ALNY) Trading Up 7.1% - Still a Buy?

Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY - Get Free Report) shares traded up 7.1% during trading on Monday . The company traded as high as $257.06 and last traded at $254.89. 351,702 shares changed hands during mid-day trading, a decline of 32% from the average session volume of 515,574 shares. The stock had previously closed at $237.98.

Analyst Upgrades and Downgrades

Several equities research analysts have recently commented on the company. HC Wainwright reissued a "buy" rating and issued a $400.00 target price on shares of Alnylam Pharmaceuticals in a research note on Monday. Sanford C. Bernstein lowered their price objective on Alnylam Pharmaceuticals from $314.00 to $310.00 and set an "outperform" rating for the company in a research report on Tuesday, January 7th. Canaccord Genuity Group upped their target price on shares of Alnylam Pharmaceuticals from $366.00 to $384.00 and gave the company a "buy" rating in a research report on Friday, November 1st. Royal Bank of Canada reiterated an "outperform" rating and set a $300.00 price target on shares of Alnylam Pharmaceuticals in a research report on Friday, November 1st. Finally, Bank of America increased their price objective on shares of Alnylam Pharmaceuticals from $307.00 to $314.00 and gave the company a "buy" rating in a report on Monday, October 14th. One research analyst has rated the stock with a sell rating, six have issued a hold rating and nineteen have assigned a buy rating to the company. According to MarketBeat, the stock has a consensus rating of "Moderate Buy" and an average price target of $298.61.

Alnylam Pharmaceuticals Price Performance

The stock has a market cap of $33.31 billion, a price-to-earnings ratio of -98.58 and a beta of 0.34. The company has a 50 day simple moving average of $248.88 and a 200-day simple moving average of $259.75. The company has a current ratio of 2.75, a quick ratio of 2.69 and a debt-to-equity ratio of 31.64.

Alnylam Pharmaceuticals (NASDAQ:ALNY - Get Free Report) last announced its earnings results on Thursday, October 31st. The biopharmaceutical company reported ($0.87) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.51) by ($0.36). The company had revenue of $500.90 million during the quarter, compared to analyst estimates of $532.91 million. The business's revenue was down 33.3% compared to the same quarter last year. During the same quarter in the previous year, the company posted $1.15 earnings per share. Research analysts expect that Alnylam Pharmaceuticals, Inc. will post -2.21 EPS for the current year.

Insiders Place Their Bets

In other news, EVP Tolga Tanguler sold 1,469 shares of the business's stock in a transaction dated Tuesday, November 26th. The shares were sold at an average price of $250.98, for a total transaction of $368,689.62. Following the transaction, the executive vice president now directly owns 13,191 shares in the company, valued at $3,310,677.18. The trade was a 10.02 % decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Also, CMO Pushkal Garg sold 1,682 shares of the company's stock in a transaction dated Tuesday, November 26th. The shares were sold at an average price of $250.98, for a total transaction of $422,148.36. Following the completion of the sale, the chief marketing officer now directly owns 17,457 shares in the company, valued at approximately $4,381,357.86. The trade was a 8.79 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold 10,122 shares of company stock valued at $2,540,455 in the last three months. 1.50% of the stock is currently owned by corporate insiders.

Hedge Funds Weigh In On Alnylam Pharmaceuticals

Institutional investors have recently bought and sold shares of the business. Souders Financial Advisors boosted its holdings in shares of Alnylam Pharmaceuticals by 1.0% during the 2nd quarter. Souders Financial Advisors now owns 3,512 shares of the biopharmaceutical company's stock worth $853,000 after buying an additional 36 shares during the period. Huntington National Bank boosted its holdings in shares of Alnylam Pharmaceuticals by 91.8% during the third quarter. Huntington National Bank now owns 94 shares of the biopharmaceutical company's stock worth $26,000 after acquiring an additional 45 shares during the period. SYM FINANCIAL Corp grew its position in shares of Alnylam Pharmaceuticals by 6.2% in the third quarter. SYM FINANCIAL Corp now owns 947 shares of the biopharmaceutical company's stock valued at $260,000 after purchasing an additional 55 shares during the last quarter. Lindbrook Capital LLC increased its stake in shares of Alnylam Pharmaceuticals by 11.1% during the third quarter. Lindbrook Capital LLC now owns 570 shares of the biopharmaceutical company's stock worth $157,000 after purchasing an additional 57 shares during the period. Finally, Wealth Enhancement Advisory Services LLC lifted its holdings in Alnylam Pharmaceuticals by 0.9% during the 4th quarter. Wealth Enhancement Advisory Services LLC now owns 6,512 shares of the biopharmaceutical company's stock worth $1,532,000 after purchasing an additional 58 shares during the last quarter. Institutional investors and hedge funds own 92.97% of the company's stock.

Alnylam Pharmaceuticals Company Profile

Alnylam Pharmaceuticals, Inc, a biopharmaceutical company, focuses on discovering, developing, and commercializing novel therapeutics based on ribonucleic acid interference. Its marketed products include ONPATTRO (patisiran) for the treatment of the polyneuropathy of hereditary transthyretin-mediated amyloidosis in adults; AMVUTTRA for the treatment of hATTR amyloidosis with polyneuropathy in adults; GIVLAARI for the treatment of adults with acute hepatic porphyria; and OXLUMO for the treatment of primary hyperoxaluria type 1.